Mutations in the RAS gene, which are thought to occur early in the adenoma-carcinoma continuum, activate the RAS/MAPK pathway independently of EGFR activation, leading to poor response to EGFR inhibitors (Amado et al., 2008; Punt, Koopman & Vermeulen, 2016). Here, EGFR is linked to adenoma.